Ignite Creation Date:
2025-12-24 @ 4:17 PM
Ignite Modification Date:
2026-01-02 @ 2:17 PM
Study NCT ID:
NCT05687266
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-10
First Post:
2022-12-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | NSCLC | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | View |
| None | Datopotamab deruxtecan (Dato-DXd, Datroway) | View |
| None | Durvalumab (Imfinzi) | View |
| None | Carboplatin | View |
| None | Chemotherapy | View |
| None | Antibody-Drug Conjugate (ADC) | View |
| None | Trophoblast cell surface protein 2 (TROP2) | View |